Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer's Mylotarg Likely To Get New Orphan, Biologics Exclusivities

Executive Summary

Return to market for leukemia drug expected to generate another orphan drug exclusivity from new indication; Mylotarg also appears on track for 12-year biologics exclusivity after being approved as BLA, rather than an NDA as it was for its initial 2000 approval.

Advertisement

Related Content

FDA's NDA And BLA Approvals: Mylotarg, Tracleer
Mylotarg Returns: US FDA Approves Pfizer's Leukemia Drug With Bonus Pediatric Indication
FDA Biologic Transition Plan Creates 'Dead Zone' For Applications, Sponsors Fear
New data could revive Pfizer's Mylotarg
Pfizer Pulls Mylotarg For Safety 10 Years After Accelerated Approval

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS121495

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel